Precision Medicine

India's 'Vaccine Capital' unveils a bold new policy at Davos, shifting from manufacturing to high-value innovation to join the world's top life sciences hubs.

The deal merges BlueRidge's broad life sciences support with Design Science's niche expertise in usability, a critical and mandatory field for FDA approval.

With a $150M+ capital raise and a top cancer immunologist on board, the T1D Fund is making a strategic play to shift from managing T1D to curing it.

BioAge Labs is developing an oral drug for diabetic macular edema, a breakthrough that could end the need for frequent, invasive eye injections for millions.

As AI transforms medicine, Lunit engages global leaders at Davos to build trust and set ethical standards for its use in the fight against cancer.

A new partnership promises up to 22% savings for employers by integrating deep pharmacy expertise, tackling one of healthcare's most complex challenges.

A new partnership between Vida Health and RxSaveCard offers employers a way to subsidize pricey weight-loss drugs outside of traditional insurance plans.

Machina Medical's novel hydrogel barrier, MFUSE, gains FDA clearance, promising to control severe bleeding in seconds and disrupt the hemostasis market.

For 10 years, McKesson's QCDR has helped oncologists navigate MIPS. Now, new measures aim to elevate patient care and prove the value of treatment.

Ascletis Pharma unveils ASC37, a next-gen, once-monthly obesity drug claiming superior potency and convenience, challenging giants like Eli Lilly.

The medtech firm reports a planned revenue decline as it divests its U.S. unit to partner Omnia Medical, betting on new tech applications for recovery.

A novel cell therapy for Parkinson's earns a key FDA designation, signaling a potential paradigm shift from managing symptoms to reversing the disease.

Carrying the Alzheimer's gene, a longevity expert has turned himself into a public experiment, documenting his radical protocol to prevent the disease.

The world's top cancer center partners with IBA in a multi-million dollar deal to install three advanced Proteus®ONE systems, heralding a new era.

A new fiber-optic platform combines laser delivery and temperature sensing, promising to reduce critical risks and enable next-generation medical devices.

Corvus Pharmaceuticals is set to unveil pivotal early data for its novel eczema drug, soquelitinib, a moment analysts call a critical milestone.

Genmab's antibody drug epcoritamab is the first of its kind to slow cancer progression in a Phase 3 trial for R/R DLBCL, offering a new path for patients.

Crosswalk Therapeutics secures a key grant to develop a therapy targeting the debilitating skeletal disease in Morquio A, a challenge current treatments can't solve.

Equinox's new EQX ARC program partners with Oura and Function to offer hyper-personalized, data-driven training for women across all life stages.

As dementia rates soar, one AI firm is using subtle signals from speech and drawing to spot cognitive decline years earlier, moving healthcare toward prevention.